After Q1 sales slip, GSK seeks to reassure investors

Share this article:

GlaxoSmithKline ended the first quarter of the year with sales dipping to $10 billion, 2% less than in the same period last year. US sales slipped 5%, to $3.4 billion. The US slide was second to Japan, where sales fell 6%, to $780 million. US pharmaceuticals and vaccines sales fell 6% during the quarter, to $3 billion, again, second to Japan where sales fell 8%.

The company attributed part of the stark contrast in performance to a high 2012 bar, and said pharmaceutical sales were also hurt by the end of the co-promotion agreement for bladder drug Vesicare in Q1 2012. Respiratory sales, meanwhile, grew 9% during the quarter. Higher prescription numbers drove US Advair sales to a 5% increase over the same period last year, while respiratory drugs Flovent and Ventolin also saw a growth spurt in US sales. None of this growth was mirrored in Europe.

The company said in February that the year was going to be a foundational one, and CEO Andrew Witty said in a statement that this quarter's performance was in line with these expectations.

Jefferies analyst Jeffery Holford titled his take on the company's sales recap “Spin Doctors,” noting that GSK's recent move to create a Global Established Products portfolio “looks like a precursor to a spin-off.”

In addition to touting its hopes for the future, GSK also called attention to an FDA advisory panel's endorsement of its experimental COPD treatment, Breo. The regulator is expected to deliver a decision within the next month, but analysts have expressed tempered enthusiasm for its potential for two reasons: physician and patient satisfaction with GSK's Advair, and the likelihood that the COPD medication does not have an asthma indication in its future.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...